Health and Healthcare
Pfizer's Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King
Published:
Last Updated:
Pfizer Inc. (NYSE: PFE) has released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy (DMD). While these results did not necessarily live up to expectations, there is a winner in this: Sarepta Therapeutics Inc. (NASDAQ: SRPT). A couple of analysts looked at these results as well and are decidedly for Sarepta over Pfizer.
Janney Capital suggested serious safety concerns, including two severe adverse effects that required hospital readmission due to severe gastrointestinal side effects and admission to a pediatric intensive care unit due to acute kidney injury with complement activation. Overall, four of the six patients treated in the study experienced nausea and vomiting, which caused transient weight loss.
The study has been paused because of the safety signals and after protocol changes. Pfizer is waiting for the final ethical review outcome to resume patient dosing.
Pfizer clearly has a plan to move forward with the guidance on the initiation of a randomized, placebo-controlled global Phase 3 study in the first half of 2020. Based on the data so far, Janney sees Sarepta leading in the race, in both timeline and quality of the clinical data.
Separately, Baird analyst Brian Skorney says Pfizer’s data related to its experimental therapy for patients with DMD falls short on both safety and efficacy. Again Skorney noted the two patients in the trial who experienced severe adverse effects and had to be hospitalized.
Shares of Pfizer closed Friday at $43.32, in a 52-week range of $36.00 to $46.47. The consensus price target is $45.57.
Sarepta closed up 17% at $151.95 per share. The 52-week range is $95.21 to $165.87, and the consensus analyst target is $204.35.
24/7 Wall St.The Average American Is Losing Their Savings Every Day (Sponsor)
If you’re like many Americans and keep your money ‘safe’ in a checking or savings account, think again. The average yield on a savings account is a paltry .4% today, and inflation is much higher. Checking accounts are even worse.
Every day you don’t move to a high-yield savings account that beats inflation, you lose more and more value.
But there is good news. To win qualified customers, some accounts are paying 9-10x this national average. That’s an incredible way to keep your money safe, and get paid at the same time. Our top pick for high yield savings accounts includes other one time cash bonuses, and is FDIC insured.
Click here to see how much more you could be earning on your savings today. It takes just a few minutes and your money could be working for you.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
